Trial Profile
Phase II Randomized Study of Continuing Treatment With Docetaxel Versus Switching to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in the First Line Treatment of Patients With Castration-Resistant Metastatic Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms SWITCH
- 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2012 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 07 Sep 2012 Actual initiation date changed from Jun 2012 to Sep 2012, as reported by ClinicalTrials.gov.